Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
NCT ID: NCT00955630
Last Updated: 2009-08-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
20 participants
INTERVENTIONAL
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
NCT00837330
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
NCT01469156
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
NCT01628354
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
NCT00395707
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
NCT00749021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be assigned to one of two groups:
Group A will receive 3 monthly injections of ranibizumab followed by an as needed injection throughout the remainder of the study Group B will receive injections of ranibizumab on an as needed basis throughout the study
You cannot take part in this study if:
1. You are pregnant or intending to become pregnant in the next 12 months or are nursing an infant
2. You are under the age of 18
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Monthly injections
3 monthly injections of ranibizumab followed by prn injections
ranibizumab
3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
PRN injections
injections of ranibizumab on a prn basis from the start of the study
ranibizumab
prn injections of ranibizumab throughout the study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ranibizumab
3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
ranibizumab
prn injections of ranibizumab throughout the study
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* active choroidal neovascularization secondary to ocular histoplasmosis
* Visual acuity between 20/25 and 20/400
Exclusion Criteria
* nursing an infant
* premenopausal women not using contraception
* prior treatment with subfoveal thermal laser
* allergy to sodium fluorescein simultaneous participation in another investigation or trial
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Retina Associates of Kentucky
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Retina Associates of Kentucky
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Kitchens, MD
Role: PRINCIPAL_INVESTIGATOR
Retina Associates of Kentucky
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina Associates of Kentucky
Lexington, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FVF 4147S
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.